|
|
Marketing Authorisations
|
|
|
|
|
An increase in serious adverse effects, particularly when bevacizumab is also added
|
|
|
|
|
|
|
|
|
|
An option when standard treatments fail or are poorly tolerated
|
|
|
|
|
|
|
|
|
|
Serious risks with no demonstrated clinical efficacy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Should blood pressure-lowering drugs be taken at bedtime?
|
|
|
|
|
|
|
|
|
|
Glecaprevir + pibrentasvir: 8 weeks of treatment also for patients with compensated cirrhosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|